Astellas Pharma Inc risk profile
25 Normal where most of the sector sits
Measured 23 October 2026 from YPH's filed statements. Recomputed nightly.
25 (Normal), driven by Market expectation at 61, over 4 weighted categories on the GENERAL profile.
What is measured
| Mechanism | Reading | Band | Direction | Driver |
|---|---|---|---|---|
| Market expectation | 61 | Stretched | Volatile | One-year price volatility — 111.3% |
| Operating pressure | 10 | Contained | Easing | Operating-margin drift — +9.1 percentage points |
| Cash conversion | 15 | Contained | Easing | Capital spending against operating cash — 0.15x |
| Leverage and coverage | 16 | Contained | Easing | Current ratio — 1.17x |
| Competitive position | Reads research_and_development, operating_income, revenue, peer cohort and disclosed transition KPIs. No reading is stored for this company. | |||
| Concentration | Reads identified supplier spend, customers above the 10% disclosure threshold and revenue by region. No reading is stored for this company. | |||
These are descriptive readings of disclosed mechanisms, not investment advice, and not a prediction. A band says where a measured input sits, never what to do about it or what happens next.
Financials, valuation and price history for Astellas Pharma Inc